Skip to main content

Table 1 Dose-toxicity relationship for each clinical study

From: Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

Study

Dose

DLTs

Number of patients evaluable for DLT

Proportion of patients who experienced a DLT

P (DLT) for true dose toxicity curve

AZD3514

250 mg QD

0

6

0%

0%

500 mg QD

0

6

0%

0%

1000 mg QD

1

6

17%

17%

1000 mg BID

3

6

50%

50%

2000 mg BID

4

4

100%

100%

AZD1208

120 mg QD

0

3

0%

0%

240 mg QD

0

3

0%

0%

480 mg QD

0

3

0%

0%

700 mg QD

1

4

25%

25%

900 mg QD

2

3

67%

67%

AZD1480

15 mg BIDa

0

4

0%

0%

20 mg BID

1

5

20%

20%

30 mg BID

1

5

20%

20%

35 mg BID

2

3

67%

67%

45 mg BID

0

2

0%

67%

AZD4877

2 mg twice weekly

0

3

0%

0%

4 mg twice weekly

0

3

0%

0%

7 mg twice weekly

0

3

0%

0%

11 mg twice weekly

0

6

0%

0%

15 mg twice weekly

2

2

100%

100%

  1. aTaken from another study on AZD1480
  2. BID: twice daily; QD: once daily